Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
Medtronic
Argus Health
Accenture
Federal Trade Commission
Mallinckrodt
UBS
QuintilesIMS
Queensland Health
Cantor Fitzgerald

Generated: January 18, 2018

DrugPatentWatch Database Preview

DURICEF Drug Profile

« Back to Dashboard

Which patents cover Duricef, and when can generic versions of Duricef launch?

Duricef is a drug marketed by Warner Chilcott and is included in three NDAs.

The generic ingredient in DURICEF is cefadroxil/cefadroxil hemihydrate. Twenty-four suppliers are listed for this compound. Additional details are available on the cefadroxil/cefadroxil hemihydrate profile page.
Summary for DURICEF
Drug patent expirations by year for DURICEF

US Patents and Regulatory Information for DURICEF

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Warner Chilcott DURICEF cefadroxil/cefadroxil hemihydrate CAPSULE;ORAL 050512-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Warner Chilcott DURICEF cefadroxil/cefadroxil hemihydrate FOR SUSPENSION;ORAL 050527-003 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Warner Chilcott DURICEF cefadroxil/cefadroxil hemihydrate CAPSULE;ORAL 050512-001 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Warner Chilcott DURICEF cefadroxil/cefadroxil hemihydrate FOR SUSPENSION;ORAL 050527-002 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Warner Chilcott DURICEF cefadroxil/cefadroxil hemihydrate TABLET;ORAL 050528-001 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Warner Chilcott DURICEF cefadroxil/cefadroxil hemihydrate FOR SUSPENSION;ORAL 050527-001 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
Accenture
McKinsey
Chinese Patent Office
Novartis
Citi
Colorcon
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot